Genelux Corporation is a clinical-stage biopharmaceutical enterprise dedicated to discovering and developing next-generation oncolytic viral immunotherapies. The company utilizes its proprietary technology platforms to engineer genetically modified strains of non-pathogenic viruses that selectively replicate within tumor tissues, destroy cancer cells, and activate the patient's immune system to combat aggressive or difficult-to-treat solid tumors.